Ackerman D M, DePalma P D, Shade M
Arzneimittelforschung. 1982;32(9):1023-5.
p-Hydroxytriamterene, the phase I metabolite of triamterene, increased sodium excretion without affecting urinary volume or potassium when administered orally to rats on sodium deficient diets at doses of 15 and 30 mg/kg. The urine of these animals also contained p-hydroxytriamterene sulfuric acid ester, the phase II metabolite of triamterene but did not contain p-hydroxytriamterene. This evidence indicates that p-hydroxytriamterene is orally active as a potassium-sparing natriuretic in rats.
氨苯蝶啶的Ⅰ相代谢产物对羟基氨苯蝶啶，以15和30毫克/千克的剂量口服给予缺钠饮食的大鼠时，可增加钠排泄，而不影响尿量或钾。这些动物的尿液中还含有氨苯蝶啶的Ⅱ相代谢产物对羟基氨苯蝶啶硫酸酯，但不含对羟基氨苯蝶啶。这一证据表明，对羟基氨苯蝶啶在大鼠中作为一种保钾利尿钠药具有口服活性。
